Publications by authors named "Rajesh Kumar Badange"

Article Synopsis
  • - The study assessed the impact of masupirdine (SUVN-502) on neuropsychiatric symptoms in patients with moderate Alzheimer's Disease, revealing no significant difference between the drug and placebo in the primary outcomes.
  • - However, post hoc analyses showed that masupirdine at doses of 50 mg and 100 mg significantly reduced agitation/aggression and psychosis symptoms in specific subgroups compared to placebo, with effects sustained for up to 26 weeks in some cases.
  • - The researchers concluded that more studies are needed to further investigate the potential benefits of masupirdine on neuropsychiatric symptoms in Alzheimer's patients.
View Article and Find Full Text PDF

A series of chemical optimizations, which was guided by in vitro affinity at histamine H receptor (H R), modulation of lipophilicity, ADME properties and preclinical efficacy resulted in the identification of 1-[2-(1-cyclobutylpiperidin-4-yloxy)-6,7-dihydro-4H-thiazolo[5,4-c]pyridin-5-yl]propan-1-one (45 e) as a potent and selective (K =4.0 nM) H R inverse agonist. Dipsogenia induced by (R)-α-methylhistamine was dose dependently antagonized by 45 e, confirming its functional antagonism at H R.

View Article and Find Full Text PDF

A series of chemical optimizations guided by in vitro affinity at a histamine H receptor (HR), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hHR K = 8.73 nM) inverse agonist at HR with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs.

View Article and Find Full Text PDF

Optimization of a novel series of 3-(piperazinylmethyl) indole derivatives as 5-hydroxytryptamine-6 receptor (5-HTR) antagonists resulted in identification of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate (5al, SUVN-502) as a clinical candidate for potential treatment of cognitive disorders. It has high affinity at human 5-HTR (K = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins.

View Article and Find Full Text PDF

A series of 4-(1-substituted piperidin-4-yloxy) benzamides and 6-(1-substituted piperidin-4-yloxy)-3,4-dihydro-2H-isoquinolin-1-one derivatives have been synthesized and tested for their binding affinity towards H3 receptor. Most of these synthesized compounds have displayed potent binding affinity for H3 receptor when tested in in vitro binding assay. Preliminary SAR studies, functional activity, pharmacokinetic profile and efficacy profile constitute the subject matter of this communication.

View Article and Find Full Text PDF

N(1)-Arylsulfonyl-3-piperazinyl indole derivatives were designed and identified as a novel class of 5-HT(6) receptors ligands. All the compounds have high affinity and antagonist activity towards 5-HT(6) receptor. The compound 7a (K(i) = 3.

View Article and Find Full Text PDF